The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
placebo 15mg/d po(10 days) +torasemide 20mg/d iv
FangYuan
Shanghai, Shanghai Municipality, China
The change of all the subjects'liquid intake and output volume change after a period(10 days) of treatment
Time frame: 2015.01-2017.12
A cumulative urine volume for 72 hours (all subjects)
Time frame: 2015.01-2017.12
Echocardiography results VS the baseline results(all subjects)
Time frame: 2015.01-2017.12
Change of right heart failure signs(all subjects)
Time frame: 2015.01-2017.12
Onset of cardiovascular event (all subjects)
Time frame: 2015.01-2017.12
Onset of serious adverse event(all subjects)
Time frame: 2015.01-2017.12
other adverse events(all subjects)
Time frame: 2015.01-2017.12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.